UnitedHealthcare UHC adds LYTENAVA to its October 2026 Medical Benefit drug review process.
As of October 1, 2026, UHC explicitly lists LYTENAVA™ (bevacizumab-vikg) in its new-to-market “Review at Launch” process for provider-administered medical-benefit drugs.
This applies to UnitedHealthcare Commercial and Community Plan.
With more than 30 million people served through its Commercial business, UHC is a major U.S. payer.
Another important step in the U.S. commercialization and reimbursement infrastructure for LYTENAVA.
Source: UnitedHealthcare Provider, October 2026 Medical Benefit Drug / Specialty Medical Injectable updates.
u/Tom_2772 — 12 days ago